abstract |
The present invention relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL insulin glargine [with 200-1000 IU of human insulin, etc.] and its use, with the proviso that the insulin glargine concentration of the formulation is not 684 U/mL. |